Topics in Focus

Background: Drug discovery and development timelines and costs are becoming unsustainable, while success rates in late-stage trials remain low and competitors are already using AI to prioritize targets, indications, and trial designs. Traditional, largely manual decision-making in discovery, pre-clinical, and early clinical stages cannot keep pace with the explosion of biological data and competitive pipelines. Objective: Use AI and advanced analytics to accelerate target identification, molecule design, biomarker discovery, trial design, and portfolio decisions, improving probability of technical and regulatory success while reducing time-to-clinic and time-to-market. Scope: • AI/ML for target identification, hit-to-lead and lead optimization, including structure- and data-driven design • In-silico prediction of ADME/Tox and safety signals to de-risk molecules earlier • AI-assisted trial design (endpoints, inclusion/exclusion, sample size, site selection, enrichment strategies) • Portfolio optimization across indications, assets, and stages based on value, risk, and capacity constraints • Integrated decision-support platforms for asset teams, governance committees, and senior R&D leadership • Feedback loops from clinical outcomes, post-marketing data, and competitor moves into R&D and portfolio models

Background: Clinicians face rising complexity (multimorbidity, new therapies, guideline changes) and documentation burden, leading to variability in care quality, burnout, and avoidable errors. Traditional CDS tools are static, rule-based, and poorly integrated into workflows. Objective: Embed AI-driven decision support and standardized, evidence-based care pathways into point-of-care workflows to improve diagnostic accuracy, treatment appropriateness, and care coordination while reducing clinician burden. Scope: • AI-assisted triage, differential diagnosis, and risk stratification in ED, outpatient, and virtual care • Dynamic, guideline- and evidence-driven care pathways integrated into EHR/EMR and order sets • AI-supported radiology, pathology, and imaging interpretation with structured reporting • Real-time clinical alerts for deterioration, sepsis, and high-risk events, tuned to reduce alert fatigue • Feedback loops from outcomes and clinician overrides to continuously improve models and pathways • Governance to ensure explainability, clinician oversight, and alignment with medical standards and liability frameworks

Background: Software delivery demands are outpacing traditional engineering capacity, creating a 10–100x gap between AI-native and legacy teams in productivity, quality, and release velocity. Objective: Systematically infuse AI into the entire SDLC to create "AI-augmented" engineering organizations that ship faster, with fewer defects, and at materially lower cost per feature. Scope: • AI pair programmers, code assistants, and test generators integrated into IDEs and CI/CD • AI-supported requirements analysis, design reviews, and architecture decision records • Automated test case generation, regression detection, and flaky test triage • AI-assisted observability, incident triage, and root-cause analysis • Developer workflow telemetry to continuously improve tools, prompts, and practices • Guardrails for secure code, IP protection, and compliance in AI-assisted development.

Background: Traditional scorecards and rule-based models are too slow and coarse to compete with AI-native players on underwriting speed, risk differentiation, and personalized pricing. Portfolios are exposed to blind spots as macro conditions, customer behavior, and fraud patterns shift faster than periodic model refresh cycles. Objective: Build AI-driven, explainable risk, credit, underwriting, and pricing engines that continuously learn from portfolio performance and market signals under strict model governance and regulatory alignment. Scope: • AI/ML models for retail, SME, corporate, and trading risk, including PD, LGD, EAD and fraud • Dynamic pricing and limit management that adapts to customer behavior and market conditions • Integrated model risk management framework with documentation, validation, and challenger models • Explainable AI (XAI) capabilities for regulators, customers, and internal decision-makers • Feedback loops from collections, recoveries, and P&L performance into model updates • Stress testing, scenario analysis, and capital optimization tied to AI risk engines

Background: Consumers and regulators are increasingly concerned about nutrition, transparency, sustainability, and labor practices. A few visible missteps on food safety, misleading claims, or social issues can destroy years of brand-building, especially in the age of social media. Objective: Build and protect a trusted food brand by aligning offerings, communication, and operations with clear commitments on quality, nutrition, transparency, and social responsibility. Scope: • Clear positioning on quality, sourcing, and nutrition, reflected in menus, packaging, and marketing • Transparent information on ingredients, allergens, and nutritional values across channels • Consistent standards for cleanliness, service, and community conduct across outlets and franchisees • Programs on waste reduction, local sourcing where feasible, and responsible marketing (kids, alcohol, etc.) • Social listening and review management with structured service-recovery and learning loops • Governance and escalation processes for crises (food safety incidents, social media storms, community issues)

Background: Online reviews, social media, and comparison platforms expose inconsistency across properties instantly, eroding brand equity and corporate contracts. Franchise, management, and ownership complexity often lead to uneven standards and fragmented improvement efforts. Objective: Ensure consistent, differentiated brand experiences and service levels across all properties and stay types, using data, standards, and coaching to protect reputation and support premium pricing and loyalty. Scope: • Clear brand and service standards translated into measurable behaviors and property-level KPIs • Centralized view of guest feedback, reviews, and social signals, with root-cause analytics • Structured quality audits, mystery shopping, and continuous-improvement programs • Capability-building programs for frontline and leadership, aligned to brand promise • Playbooks for brand-defining moments (arrival, problem resolution, loyalty recognition) • Governance and escalation pathways for underperforming properties, including turnaround plans

Background: Price volatility, tightening climate policy, and investor pressure are making traditional volume-driven exploration and production strategies unsustainable. High-cost, high-emission assets risk becoming stranded, while capital markets increasingly favor companies with disciplined returns and credible decarbonization paths. Objective: Reshape the upstream and resource portfolio around the most competitive, low-cost, and lower-carbon barrels and molecules, balancing near-term cash generation with long-term license to operate and transition. Scope: • Systematic ranking of assets by breakeven cost, emissions intensity, and above-ground risk • Portfolio decisions (develop, divest, defer, repurpose) based on capital efficiency and carbon footprint • Integration of CCUS, electrification, and methane reduction into field development and operations plans • Selective entry/exit from basins and resource types aligned with strategy and risk appetite • Governance linking capital allocation to returns, carbon metrics, and risk indicators • Partnerships and JVs where they improve access, technology, or risk sharing

Background: Health systems are rapidly adopting AI, cloud, and third-party digital tools in clinical and operational domains, often faster than governance, validation, and consent frameworks evolve. At the same time, regulations and public expectations around safety, privacy, data localization, and equity are tightening. Objective: Establish robust governance for AI, data, and digital tools that ensures clinical safety, respects data sovereignty and patient rights, and maintains trust with regulators, clinicians, and communities. Scope: • Enterprise policies for evaluation, validation, and deployment of clinical and operational AI tools • Data governance for patient and health data, including residency, sharing, secondary use, and consent • Frameworks for assessing and managing bias, fairness, and explainability in AI affecting clinical care and access • Standardized validation and monitoring processes for AI-enabled and cloud-based clinical systems • Governance bodies involving clinicians, ethicists, patients, IT, legal, and compliance to adjudicate use cases • Transparent communication to patients and staff about how data and AI are used in care and operations

Background: Fragmented records across providers, payers, and settings hinder continuity of care, population health management, and value-based care performance. Health systems and payers struggle to see a complete, longitudinal view of patients and populations. Objective: Build connected, longitudinal health records and population health analytics capabilities that support proactive care management, risk-based contracting, and equity-focused interventions. Scope: • Integration of data across EHRs, claims, labs, pharmacies, and social determinants of health into patient-centric longitudinal records • Population health stratification and registries for chronic disease, high-risk, and special populations • Care management tools and workflows for outreach, follow-up, and multidisciplinary team coordination • Analytics to identify care gaps, inequities, and high-value intervention opportunities • Reporting and intelligence for value-based contracts, quality measures, and regulatory programs • Patient-facing tools for shared records, care plans, and engagement in self-management